AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29404931 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial formulation
Number of subjects: 20
Study 29404931 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 20
Study 27966507 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-etching with 37% orthophosphoric acid for 10 seconds (Group 2a)
Number of subjects: 200
Study 27966507 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-etching with 37% orthophosphoric acid for 30 seconds (Group 2b)
Number of subjects: 200
Study 27966507 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-etching with 37% orthophosphoric acid for 60 seconds (Group 2c)
Number of subjects: 200
Study 27966507 — intervention group
Group type: COMPARATOR
Intervention: Control group without pre-etching (Group 1)
Number of subjects: 200
Study 24779438 — intervention group
Group type: EXPERIMENTAL
Intervention: ADL intervention performed by occupational therapists
Number of subjects: 118
Study 24779438 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment and care (control group)
Number of subjects: 118
Study 22466981 — intervention group
Group type: EXPERIMENTAL
Intervention: Vein collar at distal anastomosis of PTFE-grafts
Number of subjects: 345
Study 19833379 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 58
Study 19833379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 18929013 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral functional realignment orthosis
Number of subjects: 30
Study 18929013 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation program without orthosis
Number of subjects: 30
Study 15640477 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1000 mg calcium carbonate/d)
Number of subjects: 96
Study 15640477 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 96
Study 12047486 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of ayahuasca (0.6 mg DMT kg(‐1) body weight)
Number of subjects: 18
Study 12047486 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of ayahuasca (0.85 mg DMT kg(‐1) body weight)
Number of subjects: 18
Study 12047486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10076615 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatectomy with hyperthermochemohypoxic isolated liver perfusion (HILP)
Number of subjects: 16
Study 10076615 — intervention group
Group type: COMPARATOR
Intervention: Hepatectomy alone
Number of subjects: 16
Study 10076615 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatectomy with HILP
Number of subjects: 16
Study 7738505 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants asked to view the text situation from the point of view of the protagonist
Number of subjects: 0
Study 7738505 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants in Experiment 1
Number of subjects: 0
Study 8479131 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoacid supplement (KA)
Number of subjects: 16
Study 8479131 — intervention group
Group type: COMPARATOR
Intervention: Amino acid supplement (AA)
Number of subjects: 16
Study 3903069 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole administration
Number of subjects: 348
Study 3903069 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dipyridamole)
Number of subjects: 348
Study 31597315 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin (CM+Q group), administered orally for 3-5 days before catheterization.
Number of subjects: 0
Study 31597315 — intervention group
Group type: COMPARATOR
Intervention: Contrast media only (CM group).
Number of subjects: 0
Study 29678155 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Active Peaceful Playgrounds for Youth (HAPPY) intervention
Number of subjects: 0
Study 29678155 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 27131182 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrying one 1.5kg bag in each hand
Number of subjects: 9
Study 27131182 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrying one 3kg bag in each hand
Number of subjects: 9
Study 27131182 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrying one 1.5kg bag in preferred hand
Number of subjects: 9
Study 27131182 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrying one 3kg bag in preferred hand
Number of subjects: 9
Study 27131182 — intervention group
Group type: COMPARATOR
Intervention: Carrying no bags
Number of subjects: 9
Study 27131182 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrying bags (any load distribution)
Number of subjects: 9
Study 25362220 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) - 3 cycles of 5-minute ischemia in the right arm
Number of subjects: 96
Study 25362220 — intervention group
Group type: COMPARATOR
Intervention: Control group - received 1000 mL of normal saline before CAA
Number of subjects: 96
Study 22395527 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (40-120 mg)
Number of subjects: 629
Study 22395527 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (2-6 mg)
Number of subjects: 629
Study 22395527 — intervention group
Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 629
Study 20346209 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapylin + mitomycin C
Number of subjects: 79
Study 20346209 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C alone
Number of subjects: 79
Study 18625622 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg/kg tocilizumab
Number of subjects: 499
Study 18625622 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg tocilizumab
Number of subjects: 499
Study 18625622 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 499
Study 15664873 — intervention group
Group type: EXPERIMENTAL
Intervention: No dressing
Number of subjects: 18
Study 15664873 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin adhesive dressing (tegaderm)
Number of subjects: 18
Study 15664873 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulky dressing (wool and crepe)
Number of subjects: 18
Study 15664873 — intervention group
Group type: COMPARATOR
Intervention: Control (other knee)
Number of subjects: 18
Study 12028251 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of falling
Number of subjects: 1500
Study 10524421 — intervention group
Group type: EXPERIMENTAL
Intervention: Boost of 16 Gy following whole-breast irradiation of 50 Gy
Number of subjects: 5318
Study 10524421 — intervention group
Group type: COMPARATOR
Intervention: No boost
Number of subjects: 5318
Study 10524421 — intervention group
Group type: EXPERIMENTAL
Intervention: Panel evaluation
Number of subjects: 5318
Study 10524421 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitizer measurements
Number of subjects: 5318
Study 10524421 — intervention group
Group type: EXPERIMENTAL
Intervention: Panel evaluation and digitizer measurements
Number of subjects: 5318
Study 7739706 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg per day
Number of subjects: 405
Study 7739706 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg per day
Number of subjects: 405
Study 7739706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study 1962901 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMW heparin) administered subcutaneously once daily according to body weight classes (55 to 65 Factor‐Xa inhibitory U/kg) for 14 days
Number of subjects: 103
Study 1962901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 1962901 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMW heparin)
Number of subjects: 103
Study 116298 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (20 mg IV)
Number of subjects: 0
Study 30853359 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated women
Number of subjects: 14153
Study 30853359 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated women
Number of subjects: 14153
Study 28422122 — intervention group
Group type: EXPERIMENTAL
Intervention: Concept IMF (experimental)
Number of subjects: 29
Study 28422122 — intervention group
Group type: COMPARATOR
Intervention: Control IMF (current)
Number of subjects: 29
Study 25722948 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 187
Study 25722948 — intervention group
Group type: EXPERIMENTAL
Intervention: COMT met alleles interaction
Number of subjects: 187
Study 23988413 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based advance care planning tool
Number of subjects: 53
Study 23988413 — intervention group
Group type: COMPARATOR
Intervention: Control website
Number of subjects: 53
Study 21200337 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA with daily tailored feedback message (PDA + FB)
Number of subjects: 210
Study 21200337 — intervention group
Group type: EXPERIMENTAL
Intervention: PA self-monitoring
Number of subjects: 210
Study 21200337 — intervention group
Group type: COMPARATOR
Intervention: All three arms (PR, PDA, PDA + FB)
Number of subjects: 210
Study 19276559 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 0
Study 19276559 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 17905915 — intervention group
Group type: EXPERIMENTAL
Intervention: Syntactic-semantic therapy
Number of subjects: 27
Study 17905915 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic therapy
Number of subjects: 27
Study 17905915 — intervention group
Group type: COMPARATOR
Intervention: Control therapy
Number of subjects: 27
Study 15115449 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 25
Study 15115449 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study 11678746 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin levels in urine after prostatic massage
Number of subjects: 88
Study 11678746 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin concentration in EPS
Number of subjects: 88
Study 11678746 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin level in urine after massage
Number of subjects: 88
Study 9576161 — intervention group
Group type: EXPERIMENTAL
Intervention: Device I (oscillometric detection)
Number of subjects: 120
Study 9576161 — intervention group
Group type: COMPARATOR
Intervention: All devices tested
Number of subjects: 120
Study 9576161 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive measurement by oscillometry with stepped deflation
Number of subjects: 120
Study 8017999 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation
Number of subjects: 0
Study 8017999 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 8017999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8017999 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0
Study 8017999 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled data from first five randomized trials
Number of subjects: 0
Study 2828071 — intervention group
Group type: EXPERIMENTAL
Intervention: vindesine and cisplatinum
Number of subjects: 48
Study 2828071 — intervention group
Group type: COMPARATOR
Intervention: vindesine and methotrexate
Number of subjects: 48
Study 31563507 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 0
Study 31563507 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 0
Study 30017699 — intervention group
Group type: EXPERIMENTAL
Intervention: M1 a‐tDCS with postural training
Number of subjects: 65
Study 30017699 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral cerebellar a‐tDCS with postural training
Number of subjects: 65
Study 30017699 — intervention group
Group type: COMPARATOR
Intervention: Sham a‐tDCS with postural training
Number of subjects: 65
Study 30017699 — intervention group
Group type: COMPARATOR
Intervention: Postural training alone
Number of subjects: 65
Study 30017699 — intervention group
Group type: COMPARATOR
Intervention: Cerebellar a‐tDCS alone
Number of subjects: 65
Study 28949895 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced arm (phone-based intervention)
Number of subjects: 41
Study 28949895 — intervention group
Group type: COMPARATOR
Intervention: Basic arm (results simply distributed)
Number of subjects: 41
Study 26673292 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene engineering technologies of angiogenesis stimulation as an independent method of treatment in comprehensive conservative therapy (80 patients)
Number of subjects: 160
Study 26673292 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene engineering technologies of angiogenesis stimulation as comprehensive treatment in combination with revascularizing operations (80 patients)
Number of subjects: 160
Study 26673292 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene engineering technologies of angiogenesis stimulation
Number of subjects: 160
Study 23587630 — intervention group
Group type: EXPERIMENTAL
Intervention: Compact catheter
Number of subjects: 125
Study 23587630 — intervention group
Group type: COMPARATOR
Intervention: Standard hydrophilic coated catheters
Number of subjects: 125
Study 20729532 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study 20729532 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40
Study 18582373 — intervention group
Group type: COMPARATOR
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 16
Study 17099421 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance elastography (MRE) using bSSFP sequence
Number of subjects: 14
Study 17099421 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up studies
Number of subjects: 14
Study 12808401 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpreserved lubricants, topical steroidal and nonsteroidal anti-inflammatory agents, punctal plugs for aqueous-deficient dry eye, mechanical removal of filaments, hypertonic saline, mucolytic agents, and bandage contact lenses.
Number of subjects: 0
Study 12808401 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- and postoperative ocular surface management strategies.
Number of subjects: 0
Study 12808401 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate medications or additional measures to manage the tear film and ocular surface.
Number of subjects: 0
Study 10954213 — intervention group
Group type: EXPERIMENTAL
Intervention: Emollients (4 different types applied thickly on half of the face)
Number of subjects: 46
Study 10954213 — intervention group
Group type: EXPERIMENTAL
Intervention: White petrolatum (one of the emollients)
Number of subjects: 46
Study 10954213 — intervention group
Group type: COMPARATOR
Intervention: Untreated control (the other half of the face without emollients)
Number of subjects: 46
Study 8796369 — intervention group
Group type: EXPERIMENTAL
Intervention: Lp(a) fractions containing mainly small apo(a) isoforms (either B or S1)
Number of subjects: 0
Study 8796369 — intervention group
Group type: EXPERIMENTAL
Intervention: Lp(a) fractions containing mainly high molecular mass isoforms (either S3 or S4)
Number of subjects: 0
Study 8796369 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in Kd as a function of the relative content in isoforms of high molecular mass
Number of subjects: 0
Study 1610631 — intervention group
Group type: EXPERIMENTAL
Intervention: Demand top-ups of 0.25% plain bupivacaine 10 ml
Number of subjects: 3
Study 1610631 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of 0.125% plain bupivacaine 10 ml h‐1
Number of subjects: 3
Study 1610631 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled extradural analgesia (PCEA) delivering 3-ml boluses of 0.25% bupivacaine
Number of subjects: 3
Study 3968329 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitolterol aerosol (three sprays, 1.11 mg)
Number of subjects: 120
Study 3968329 — intervention group
Group type: COMPARATOR
Intervention: Albuterol aerosol (two sprays, 180 mcg)
Number of subjects: 120
Study 3968329 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitolterol aerosol
Number of subjects: 120
Study 30801888 — intervention group
Group type: EXPERIMENTAL
Intervention: Male ophthalmologists
Number of subjects: 282
Study 30801888 — intervention group
Group type: COMPARATOR
Intervention: Female ophthalmologists
Number of subjects: 282
Study 28786197 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese Health Improvement Profile (CHIP) intervention
Number of subjects: 137
Study 28786197 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 137
Study 27444660 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO‐6950 (200 mg)
Number of subjects: 25
Study 27444660 — intervention group
Group type: COMPARATOR
Intervention: Montelukast (10 mg)
Number of subjects: 25
Study 27444660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 24534331 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic status measures (education, household expenditures, household assets, subjective wealth, father's education)
Number of subjects: 3993
Study 24534331 — intervention group
Group type: COMPARATOR
Intervention: General population across all SES groups
Number of subjects: 3993
Study 22160854 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg daily plus TMZ 150 mg/m(2)/day for 5 days every 28 days (NEIAEDs)
Number of subjects: 32
Study 22160854 — intervention group
Group type: COMPARATOR
Intervention: Everolimus (various doses) plus TMZ (150 mg/m(2)/day) (EIAEDs)
Number of subjects: 32
Study 21055801 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 μg/day paricalcitol
Number of subjects: 281
Study 21055801 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 μg/day paricalcitol
Number of subjects: 281
Study 21055801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study 17656129 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional technique
Number of subjects: 14
Study 17656129 — intervention group
Group type: COMPARATOR
Intervention: Bone-condensing technique
Number of subjects: 14
Study 16583596 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total dentifrice (CTD)
Number of subjects: 11
Study 16583596 — intervention group
Group type: COMPARATOR
Intervention: Colgate Cavity Protection (CCP)
Number of subjects: 11
Study 11918909 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting plus abciximab
Number of subjects: 162
Study 11918909 — intervention group
Group type: COMPARATOR
Intervention: Alteplase plus abciximab
Number of subjects: 162
Study 10557953 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low doses of estrogen combined with vitamin D and calcium
Number of subjects: 0
Study 10557953 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy with very low doses of estrogen
Number of subjects: 0
Study 8556189 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide (0.1 to 8.0 ng/mL)
Number of subjects: 24
Study 8556189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1683403 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline 1.0 mg
Number of subjects: 140
Study 1683403 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline 0.75 mg
Number of subjects: 140
Study 1683403 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline 0.5 mg
Number of subjects: 140
Study 1683403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 7137550 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 100
Study 7137550 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 100
Study 7137550 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane and Enflurane
Number of subjects: 100
Study 31685833 — intervention group
Group type: EXPERIMENTAL
Intervention: hTERC gene examination using fluorescence in situ hybridization (FISH)
Number of subjects: 1200
Study 31685833 — intervention group
Group type: EXPERIMENTAL
Intervention: HR‐HPV infection
Number of subjects: 1200
Study 28975239 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle-sparing technique (n=11)
Number of subjects: 19
Study 28975239 — intervention group
Group type: COMPARATOR
Intervention: Muscle-cutting technique (n=8)
Number of subjects: 19
Study 26995371 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (AEs) reported after hospital discharge
Number of subjects: 48118
Study 26995371 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious adverse events (SAEs) reported after hospital discharge
Number of subjects: 48118
Study 26995371 — intervention group
Group type: EXPERIMENTAL
Intervention: Distribution of nonserious AEs across system organ classes
Number of subjects: 48118
Study 26995371 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of more SAEs
Number of subjects: 48118
Study 26995371 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of fewer SAEs
Number of subjects: 48118
Study 23686130 — intervention group
Group type: EXPERIMENTAL
Intervention: REHACOP (neuropsychological rehabilitation)
Number of subjects: 84
Study 23686130 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 84
Study 21394496 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 529
Study 21394496 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 529
Study 19639511 — intervention group
Group type: COMPARATOR
Intervention: Vaginal delivery (VD)
Number of subjects: 201
Study 19639511 — intervention group
Group type: EXPERIMENTAL
Intervention: Caesarean section (CS)
Number of subjects: 201
Study 19639511 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative previous birth experience
Number of subjects: 201
Study 19639511 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous CS
Number of subjects: 201
Study 17316466 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of hydrocortisone
Number of subjects: 0
Study 17316466 — intervention group
Group type: COMPARATOR
Intervention: Bolus application of hydrocortisone
Number of subjects: 0
Study 14684673 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 0
Study 14684673 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 0